Talk:International Prostate Symptom Score
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
Text needing relation to subject
editThe following section was previously in the article, but I moved it here, because I think that it needs to be related to the test before reinsertion in the article. Now it says nothing than what is already given in the article on benign prostatic hyperplasia, but what we would need is a specific correlation between IPSS score and how to handle the BPH most efficiently. Mikael Häggström (talk) 14:43, 22 November 2011 (UTC)
Penign prostatic hyperplasia
editPatients with benign prostatic hyperplasia (BPH) either 1) may need no treatment, just observation, because many patients stay the same or even improve over the years, or 2) many need only medical treatment, a) either only with an alpha-1-adrenergic antagonist, e.g. tamsulosin, b) with a 5-alpha reductase inhibiter as monotherapy e.g. dutasteride or c) with an alpha-1-adrenergic antagonist plus a 5-alpha reductase inhibitor (e.g. tamsulosin and dutasteride as combination therapy), depending on the severity of their symptoms, or 3) may need surgical intervention.[1][2][3][4][5]
BPH patients are treated with surgery if a) BPH becomes a risk factor for upper urinary tract damage (i.e. damage to the ureters and kidneys, which may include severe damage such as pyelonephritis, hydronephrosis, and renal failure), or b) if the symptoms of BPH on the lower urinary tract become serious (i.e. 1) recurrent infections, or 2) bladder decompensation, i.e. urinary retention >25% immediately after voiding the bladder). In all non-emergency cases, not only the severity of BPH symptoms, but also the subjective quality-of-life of the patient and the wishes of the patient are taken into account before deciding on surgery.
- ^ Patel AK, Chapple CR. Benign prostatic hyperplasia: treatment in primary care. BMJ. 2006 Sep 9;333(7567):535-9. Review.
- ^ Wasserman NF. Benign prostatic hyperplasia: a review and ultrasound classification. Radiol Clin North Am. 2006 Sep;44(5):689-710, viii. Review.
- ^ Burnett AL, Wein AJ. Benign prostatic hyperplasia in primary care: what you need to know. J Urol. 2006 Mar;175(3 Pt 2):S19-24. Review.
- ^ Dull P, Reagan RW Jr, Bahnson RR. Managing benign prostatic hyperplasia. Am Fam Physician. 2002 Jul 1;66(1):77-84. Review.
- ^ McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003 Dec 18;349(25):2387-98. Fulltext
Dead link
editThe url http://www.usrf.org/questionnaires/AUA_SymptomScore.html no longer works. — Preceding unsigned comment added by 81.144.156.34 (talk) 08:01, 30 August 2012 (UTC)
